September 18, 2025
This video reviews the final overall survival results from the phase 3 FLAURA2 trial comparing first-line osimertinib plus chemotherapy with osimertinib alone in EGFR-mutated advanced non-small cell lung cancer. The analysis showed that adding chemotherapy to osimertinib led to improved overall survival compared with monotherapy, with benefits observed across multiple patient subgroups. These findings further inform first-line treatment decisions in EGFR-mutated advanced NSCLC.
Related Posts
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
